Canbridge Pharmaceuticals (HKSE:01228) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01228 Canbridge Pharmaceuticals Inc HKSE:01228
48 GF Score
Price HK$2.05
GF Value HK$0.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01228
48GF Score
Canbridge Pharmaceuticals Inc HKSE:01228
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of HK$2.05 is trading 439.5% above its estimated GF Value™ of HK$0.38. GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:01228:

  • FFO:
  • GF Value™: HK$0.38 vs. price of HK$2.05 (439.5% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score

Get the complete analysis for HKSE:01228

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.05
Price
HK$0.38
GF Value